Article
Chemistry, Medicinal
Tingting Sun, Qingquan Wei, Peng Gao, Yongjie Zhang, Qing Peng
Summary: The study investigated cytokine and chemokines profiling in the aqueous humor of nAMD patients, finding lower levels of basic fibroblast growth factor and RANTES, and higher levels of VEGF-A compared to the control group. After IVR treatment, levels of Eotaxin increased while VEGF-A decreased in nAMD patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Medicine, General & Internal
Junyeop Lee, You Na Kim, June-Gone Kim
Summary: Monthly alternating injections of aflibercept and bevacizumab were effective in preventing deterioration in patients with neovascular age-related macular degeneration who were not responding to bimonthly injections.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Jae-Hui Kim, Jong-Woo Kim, Chul-Gu Kim
Summary: This study revealed a trend in the selection of ranibizumab and aflibercept for initial treatment of neovascular AMD and PCV, with ranibizumab preferred in older patients and those with type 3 MNV, and aflibercept highly preferred in patients with PCV. The variance in patient characteristics and efficacy of the two agents may have influenced this trend.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Mirataollah Salabati, Anthony Obeid, Raziyeh Mahmoudzadeh, Omesh Gupta, Allen Chiang, Marc Spirn, Michael A. Klufas, Jason Hsu
Summary: This study aimed to evaluate the efficacy changes of stable nAMD patients on aflibercept who switched to ranibizumab. The results showed that patients in the switch group experienced worsening of visual acuity and central foveal thickness, while those in the aflibercept group remained relatively stable.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2022)
Article
Medicine, Research & Experimental
Xuan Cao, Jaron Castillo Sanchez, Tapan P. Patel, Zhiyong Yang, Chuanyu Guo, Danyal Malik, Anuoluwapo Sopeyin, Silvia Montaner, Akrit Sodhi
Summary: A study found that aflibercept may reduce the number of anti-VEGF treatments and increase the likelihood of weaning off medication compared to bevacizumab for patients with nvAMD. Therefore, the choice of therapy is crucial when treating patients with nvAMD.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Medicine, Research & Experimental
Gideon Obasanmi, Matthew R. Zeglinski, Ella Hardie, Anna-Catharina Wilhelm, Christopher T. Turner, Sho Hiroyasu, Wendy A. Boivin, Yuan Tian, Hongyan Zhao, Eleanor To, Jing Z. Cui, Jeanne Xi, Hyung-Suk Yoo, Manjosh Uppal, David J. Granville, Joanne A. Matsubara
Summary: Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in the elderly and is associated with abnormal blood vessel growth. This study explored the relationship between the protease Granzyme B (GzmB) and the antiangiogenic factors Thrombospondin (TSP)-1 and TSP-2 in eyes with neovascular AMD. The study found that TSP-1 and TSP-2 are substrates of GzmB and that the proteolysis of these factors by GzmB may contribute to neovascular AMD-related choroidal neovascularization (CNV).
LABORATORY INVESTIGATION
(2023)
Review
Medicine, General & Internal
Robyn H. Guymer, Thomas G. Campbell
Summary: Age-related macular degeneration is becoming increasingly important due to aging populations and increased longevity. It affects individuals older than 55 years and threatens high-acuity central vision needed for important tasks. Advances in retinal imaging have identified biomarkers of progression. New treatments for neovascular AMD offer potentially longer-lasting effects, but a treatment for atrophic late-stage AMD is still being developed. An effective intervention for early-stage disease or prevention of late-stage AMD has not been found yet, and our understanding of underlying mechanisms continues to evolve.
Article
Ophthalmology
Jae Yong Park, Min-Ji Kang, Bum Gi Kim, Kyu Ho Chung, Ha Eun Sim, Seong Woo Lee, Jae Suk Kim, Hyeon Seok Lee, Je Hyung Hwang
Summary: The study found that during the development of CNV, there is a significant increase in choroidal thickness in the corresponding subfield. Additionally, three months before the development of CNV, the choroidal thickness in the central subfield also significantly increases. Regular measurement of choroidal thickness may help in predicting CNV development.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2021)
Article
Ophthalmology
Imoro Zeba Braimah, Winfried M. Amoaku
Summary: The study found that intravitreal ziv-aflibercept (IVZ) is associated with significant improvement in best-corrected visual acuity (BCVA) and reduction in central macular thickness (CMT) in patients with diabetic macular edema (DME).
Article
Multidisciplinary Sciences
I-Hsin Ma, Yun Hsia, Yi-Ting Hsieh, Tzyy-Chang Ho, Tso-Ting Lai, Chung-May Yang, Chang-Hao Yang
Summary: The study found that using aflibercept monotherapy is as effective as combining PDT with ranibizumab in treating PCV patients, with better prognosis observed in non-pachychoroid patients.
SCIENTIFIC REPORTS
(2021)
Review
Cell Biology
Aniket Ramshekar, Haibo Wang, M. Elizabeth Hartnett
Summary: AMD is a major cause of blindness worldwide, with neovascular AMD leading to vision loss. The current standard of care with anti-angiogenic agents is only effective in around 50% of AMD cases. Studies have shown that Rac1 activation plays a crucial role in the invasion of choroidal endothelial cells into the neural retina in AMD.
Article
Ophthalmology
Rachael C. Heath Jeffery, Syed Aqif Mukhtar, Derrick Lopez, David B. Preen, Ian L. McAllister, David A. Mackey, Nigel Morlet, William H. Morgan, Fred K. Chen
Summary: The study reported the age-standardized annual incidence of blindness due to AMD and the treatment patterns in Australia. The incidence of blindness rose during the PDT era but declined in the IVT era. The age at AMD blindness registration increased over time, with different trends in PDT and IVT usage.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Marco Pellegrini, Federico Bernabei, Andrea Mercanti, Stefano Sebastiani, Enrico Peiretti, Claudio Iovino, Giamberto Casini, Pasquale Loiudice, Vincenzo Scorcia, Giuseppe Giannaccare
Summary: This study evaluated choroidal vascular changes in nAMD patients treated with aflibercept injections, showing significant decreases in choroidal thickness and vascularity after treatment, which were significantly correlated with baseline choroidal vascularity index.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mayank Choubey, Puran Bora
Summary: Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in adults, with significant visual disability and central vision loss. Adiponectin (APN) and its receptors (AdipoRs) play a central role in metabolic disorders and ocular pathology. This review summarizes the association of APN/AdipoRs with retinal diseases, specifically AMD and diabetic retinopathy, and presents original research on the inhibition of choroidal neovascularization (CNV) in a mouse model with APN-derived peptides.
Article
Medicine, General & Internal
Chirag D. Jhaveri, Adam R. Glassman, Frederick L. Ferris, Danni Liu, Maureen G. Maguire, John B. Allen, Carl W. Baker, David Browning, Matthew A. Cunningham, Scott M. Friedman, Lee M. Jampol, Dennis M. Marcus, Daniel F. Martin, Carin M. Preston, Cynthia R. Stockdale, Jennifer K. Sun
Summary: The relative efficacy of administering aflibercept monotherapy compared with bevacizumab followed by aflibercept if there is insufficient improvement in eyes with diabetic macular edema is uncertain.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Ophthalmology
Roberto dell'Omo, Mariaelena Filippelli, Gianni Virgili, Francesco Bandello, Giuseppe Querques, Paolo Lanzetta, Teresio Avitabile, Francesco Viola, Michele Reibaldi, Francesco Semeraro, Luciano Quaranta, Stanislao Rizzo, Edoardo Midena, Giuseppe Campagna, Ciro Costagliola
Summary: The number of eye surgical procedures in Italy significantly decreased during the lockdown due to the COVID-19 epidemic, with only 70% of recommended surgeries being performed. Elective surgeries decreased by 96.2%, urgent surgeries by 49.7%, and intravitreal injections by 48.5% during the lockdown period.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2022)
Letter
Ophthalmology
Daniele Veritti, Valentina Sarao, Francesco Bandello, Paolo Lanzetta
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2022)
Letter
Ophthalmology
Daniele Veritti, Valentina Sarao, Francesco Bandello, Paolo Lanzetta
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2022)
Letter
Ophthalmology
Daniele Veritti, Valentina Sarao, Francesco Bandello, Paolo Lanzetta
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2022)
Letter
Ophthalmology
Daniele Veritti, Valentina Sarao, Francesco Bandello, Paolo Lanzetta
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Ophthalmology
Matias Iglicki, Catharina Busch, Paolo Lanzetta, Valentina Sarao, Daniele Veritti, Nicolo Rassu, Marco Lupidi, Zafer Cebeci, Samantha Fraser-Bell, Carolina Bernal-Morales, Anna Sala-Puigdollers, Javier Zarranz-Ventura, Roberto Gallego-Pinazo, Aniruddha Maiti, Giuseppe D'Amico Ricci, Patricia Udaondo, Anat Loewenstein, Jay Chhablani, Dinah Zur
Summary: This study compared the visual and anatomical outcomes of vitrectomized and non-vitrectomized eyes treated with dexamethasone (DEX) implant for diabetic macular oedema (DMO). The results showed significant improvement in both groups after 12 months of follow-up, with no significant difference between the two.
Review
Medicine, General & Internal
Daniele Veritti, Valentina Sarao, Valentina Soppelsa, Carla Danese, Jay Chhablani, Paolo Lanzetta
Summary: The use of anti-VEGF agents can significantly improve visual acuity in patients with nAMD, with a proactive treatment approach yielding better outcomes. Younger patients with lower baseline visual acuity and receiving a higher number of injections also have better treatment results.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Daniele Veritti, Valentina Sarao, Gianluca Gorni, Paolo Lanzetta
Summary: The study utilized a mathematical model to evaluate the impact of different treatment intervals of anti-VEGF drugs on intraocular VEGF inhibition, finding that fixed treatment regimens can maintain the proportion of free VEGF at safe levels.
Review
Ophthalmology
Daniele Veritti, Valentina Sarao, Jay Chhablani, Anat Loewenstein, Paolo Lanzetta
Summary: This study reviewed the ideal setting for intravitreal injection (IVI) administration of vascular endothelial growth factor (VEGF) inhibitors and provided recommendations. The research utilized content analysis, literature review, and international survey methods. The findings suggest that different injection settings have no significant impact on perioperative complications, and choosing the appropriate clinical environment can optimize patient management and improve treatment effectiveness, quality, productivity, and capacity.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Pharmacology & Pharmacy
Daniele Veritti, Valentina Sarao, Francesco Di Bin, Paolo Lanzetta
Summary: This study evaluated the effects of different dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free VEGF to total VEGF. The results showed that an 8 mg dosage administered every 12-15 weeks can effectively inhibit VEGF.
Review
Ophthalmology
Daniele Veritti, Leopoldo Rubinato, Valentina Sarao, Axel De Nardin, Gian Luca Foresti, Paolo Lanzetta
Summary: This narrative review provides an overview of the dangers, controversial aspects, and implications of artificial intelligence (AI) use in ophthalmology and other medical-related fields.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Review
Cell Biology
Simone Dal Bello, Deborah Martinuzzi, Yan Tereshko, Daniele Veritti, Valentina Sarao, Gian Luigi Gigli, Paolo Lanzetta, Mariarosaria Valente
Summary: This review discusses the established standards of care for optic pathway gliomas (OPGs), and highlights emerging therapeutic strategies and potential alternative therapies for OPG treatment. It also addresses the challenges of restoring visual function in cases of optic nerve damage and explores ongoing research in this area, particularly involving stem cells.
